eTheRNA immunotherapies has differentiated mRNA capabilities clinically proven to generate highly-specific T cells by combining mRNA chemistry solutions with unique TriMix technology. eTheRNA also has innovative, differentiated lipid formulations that enable targeted delivery and tailored  biodistribution with preclinical demonstration of superiority to competing LNPs. eTheRNA has patent protected process technologies and disruptive manufacturing  capabilities that promise faster development of a temperature stable mRNA product.

The impact of combining unique mRNA chemistry, TriMix technology and proprietary formulations on immune  modulation and T cell responses is what makes eTheRNA a competitive mRNA company. eTheRNA’s differentiated tools are combined to generate a pipeline of late pre-clinical stage products, including  therapeutic- and prophylactic- vaccines and therapeutic oncology programs.

eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology.